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to basal levels. SOCS3 expression was 
unchanged. Consequently, the role of 
SOCS proteins in uremic sarcopenia 
remains elusive. What other pathways 
may be involved? Because JAK-2 phos-
phorylation can lead to activation of the 
mitogen-activated protein kinase and 
other signaling pathways, it is conceivable 
that multiple pathways may be working 
separately or in concert to countermand 
changes in SOCS expression.11 Alterna-
tively, angiotensin II and glucocorticoids, 
which are elevated in uremia, may be 
playing unknown roles. Under conditions 
of inflammation, activated macrophages 
reside in fat tissues and release proinflam-
matory cytokines such as interleukin-6 
and tumor necrosis factor-α, which may 
activate systemic responses.12 What the 
work of Cheung et al.1 underscores is how 
complex intracellular signaling is.
The data presented by Cheung and 
colleagues1 emphasize the importance 
of melanocortin signaling in the patho-
genesis of uremic cachexia. Above and 
beyond its effect on nutrition, inhibition 
of MC4-R signaling may attenuate muscle 
atrophy by normalizing expression of key 
proteins that act to maintain muscle mass. 
These new findings bolster the hypothesis 
that MC4-R antagonists may provide new 
strategies for treatment of multiple facets 
of CKD-associated cachexia.
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HNF1β and defective 
nephrogenesis: a role for 
interacting partners?
Evelyne Fischer1 and Marco Pontoglio1
The genetic program controlled by transcription factors can be 
modulated by multiple mechanisms. Binding of coactivators or 
corepressors, for example, can modulate the transcription of target 
genes. Dudziak and colleagues identified novel HNF1β-interacting 
proteins that, when overexpressed, affect nephrogenesis. These 
results could improve our understanding of the way HNF1β controls 
kidney development.
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Hepatocyte nuclear factors 1α and 1β 
(HNF1α/TCF1 and HNF1β/TCF2) are 
two closely related homeobox proteins 
whose ancestral gene duplication appeared 
during evolution with the first vertebrates. 
These two proteins contain three func-
tional domains: a dimerization domain at 
the N terminus, a POU-homeobox-DNA-
binding domain, and a C-terminal transac-
tivation domain. HNF1α and HNF1β share 
strong homologies in both the dimerization 
and the DNA-binding domains, account-
ing for the fact that the two proteins are 
able to heterodimerize and to bind to the 
same DNA target sequences.1,2
During development, HNF1β  is 
expressed starting with the first steps 
during organogenesis of liver, lung, pan-
creas, digestive tract, and kidney. In all 
these organs, the expression of HNF1β, 
which persists also in the adult stage, is 
restricted to polarized epithelia. The anal-
ysis of mouse models of HNF1β inacti-
vation has provided new insights into 
its role. HNF1β-deficient mice die very 
early, between 6.5 and 7.5 days postcoi-
tus, because of a defective extraembryonic 
visceral endoderm differentiation,3,4 
preventing the analysis of its functions 
during organogenesis. Liver-specific 
HNF1β inactivation in mice results in 
an abnormal gallbladder and an almost 
complete lack of intrahepatic bile ducts.5 
Overexpression of a dominant-negative 
form of HNF1β or its gene inactivation 
in already formed renal tubules leads to a 
drastic form of polycystic kidney disease 
(PKD).6,7 Gene expression analysis com-
bined with chromatin immunoprecipita-
tion in HNF1β-deficient kidney has shown 
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a direct transcriptional hierarchy between 
HNF1β and several targets, including 
Umod, Pkhd1, and Pkd2,6,7 genes whose 
mutations are involved in cystic disease. 
Interestingly, tubular dilations in several 
PKD mouse models (HNF1β- or Kif3a-
renal-deficient mice and Pck rats carrying 
a mutation in Pkhd1) are triggered by the 
loss of orientation of mitotic spindles in 
renal epithelial cells during tubular elon-
gation.8,9 Interestingly, the formation of 
cysts in Kif3a-deficient kidneys is associ-
ated with the complete lack of primary 
cilia,10 indicating that these organelles are 
probably required for planar cell polari-
zation of the tubular epithelium. How-
ever, the mechanisms by which primary 
cilia regulate planar cell polarization still 
remain to be elucidated.
Recently, an additional direct HNF1β 
target has been identified: Ma and col-
leagues have shown that the expression 
of SOCS3 is increased in animals with 
a kidney-specific deletion of HNF1β.11 
Increased levels of SOCS3 inhibit hepato-
cyte growth factor-induced tubulogenesis 
in vitro by decreasing phosphorylation of 
ERK and STAT3. Conversely, knock-down 
of SOCS3 partially rescues defective tub-
ulogenesis in cells expressing dominant-
negative mutant HNF1β.
The important role played by HNF1β 
in organogenesis and physiopathology 
is documented by the complex pheno-
type presented by patients who carry 
heterozygous mutations in this gene. 
These patients suffer from a particular 
form of type 2 diabetes mellitus called 
maturity-onset diabetes of the young type 
5 (MODY5), characterized by defective 
insulin secretion and early age of onset.12 
This diabetic phenotype can be associated 
with pancreas atrophy, genital malforma-
tions, abnormal liver function tests, and 
neonatal cholestasis (reviewed by Igarashi 
et al.13). However, the most penetrant 
phenotypic trait is represented by kidney 
malformations. The most common renal 
abnormality involves the formation of 
cysts. This syndrome is described as renal 
cysts and diabetes (RCAD; reviewed by 
Igarashi et al.13). The spectrum of congeni-
tal renal cystic abnormalities includes sim-
ple cysts, multicystic renal dysplasia, and 
hypoplastic glomerulocystic kidney dis-
ease. Renal dysfunction is often severe and 
can lead to kidney failure. Recent studies 
have suggested that HNF1β mutations are 
very commonly found in young patients 
with renal malformations. Approximately 
30% of children with hypodysplasia and/
or cysts, or fetuses with hyperechogenic 
bilateral kidneys, carry HNF1β muta-
tions.14,15 These findings suggest that 
mutations of HNF1β may represent the 
most common cause of congenital renal 
abnormalities.
The clinical spectrum of renal mani-
festations linked to HNF1β mutations 
is very broad, without any clear correla-
tion between the type of mutation and 
the phenotype. Several observations 
revealed that de novo mutations affect a 
considerable proportion (50%) of patients 
and that more than 40% are represented 
by large genomic deletions, suggesting an 
intrinsic instability of the TCF2 locus.14,15 
Interestingly, the HNF1β gene is located 
in a region flanked by segmental duplica-
tions. These long duplicated chromosomal 
regions are susceptible to unequal crossing 
over between the segmental duplications. 
This genomic rearrangement can lead to 
the excision of the intervening HNF1β 
chromosomal region.16 Interestingly, it has 
been shown that PKD genes can undergo 
somatic loss of heterozygosity, leading to a 
cystic phenotype.17 A similar somatic loss 
of heterozygosity could occur for HNF1β 
thanks to the genomic instability of the 
TCF2 locus. This mechanism could play 
a crucial role in the heterogeneity of the 
observed phenotype. Depending on the 
developmental stage, somatic mutations 
could give rise to hypodysplasia or cysts.
To date, more than 50 different muta-
tions of HNF1β responsible for various 
renal developmental defects have been 
identified in MODY5 patients. These 
mutations concern all three functional 
domains of the protein. The molecu-
lar mechanisms by which mutations of 
HNF1β can give rise to renal disease can 
be multiple. They could affect protein 
stability, DNA-binding capacity, or trans-
activating properties through impaired 
coactivator recruitment. Studies on both 
HNF1α and HNF1β have clearly demon-
strated that truncation of the C-terminal 
transactivation domain, as well as point 
mutations, can abolish transcriptional 
activation.18–20 Furthermore, it has been 
shown that some mutations may abolish 
the interaction of classical partners of 
transcription factors involved in chroma-
tin modifications. Different mutations 
resulting in protein truncation, amino 
acid substitutions, or frameshift dele-
tions in different domains of HNF1β have 
been analyzed.19 The loss of transactiva-
tion capacity did not necessarily correlate 
with loss of DNA binding. In particular, 
some of the mutations compromise the 
ability of HNF1β to bind the histone-
acetyltransferases CBP and P/CAF.
An alternative way to explain the vari-
ous renal phenotypic manifestations of 
HNF1β mutations could be related to the 
fact that the genetic program controlled 
by HNF1β depends on the recruitment of 
HNF1β
ZFP36L1
DCoH CBP
P/CAFE4F1(?)
Gene expression
HDAC1
Figure 1 | The genetic program controlled by HNF1β is modulated by several interacting 
partners. DCoH, CBP, P/CAF, and HDAC1 have already been described as regulators of the 
transcriptional activation of HNF1β. E4F1 and ZFP36L1 are novel interactors identified by Dudziak 
and colleagues.21 ZFP36L1 downregulates the transcriptional activity of HNF1β in vitro.
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coactivators expressed or needed at differ-
ent stages during organogenesis (Figure 1). 
Mutations that impair binding of partners 
needed for the early steps of nephrogen-
esis could lead to hypodysplastic kidneys, 
whereas disruption of the interaction of 
coactivators involved in later steps, after 
renal tubulogenesis, could give rise to a 
cystic phenotype.
Few studies have attempted to iden-
tify new partners of HNF1β. A paper by 
Dudziak et al.21 (this issue) addresses 
this problem. Dudziak and colleagues 
identified two novel proteins that inter-
act in vitro with HNF1β by screening 
a fetal kidney complementary DNA 
library with a bacterial two-hybrid sys-
tem. These novel partners were shown 
to affect the morphogenetic processes 
involved in nephrogenesis in Xenopus. 
The first, E4F1, is a zinc finger transcrip-
tion factor that can induce chromatin 
modifications in association with p53. 
This protein interacts with BMI1, a com-
ponent of the Polycomb complex. Over-
expression of E4F1 leads to an increase 
in pronephros size due to a thickening 
of the duct or an increase in the length 
of the tubule. The second, ZFP36L1, 
belongs to the tristetraprolin family of 
CCCH zinc finger proteins that shuttles 
between nucleus and cytoplasm. Whereas 
its nuclear function is still unknown, it 
plays a role in initiating RNA degrada-
tion by recruiting RNA decay enzymes. 
ZFP36L1 overexpression results in vari-
able pronephric phenotypes, including 
cysts, thickening of the tubule, or devel-
opmental defect resulting in a rudi-
mentary organ. ZFP36L1 is essentially 
localized in the cytoplasm, with some 
possible colocalization with HNF1β at 
the nuclear membrane. Importantly, the 
authors showed that ZFP36L1 clearly 
affects the transactivation potential of 
HNF1β. Further studies are needed to 
confirm the in vivo interaction of these 
two proteins with HNF1β. It would be 
interesting to see whether MODY5 
mutations could interfere with the bind-
ing of these new partners. The possibility 
that renal abnormalities in patients with-
out HNF1β mutations could be attrib-
uted to mutations in these partners was 
also investigated. However, in a small 
cohort of patients with unexplained 
renal disease, no mutations in ZFP36L1 
were found.
In conclusion, this study showed that 
these novel interacting partners can 
modify the transactivating properties of 
HNF1β. The characterization of these 
effectors could help to understand bet-
ter the way HNF1β controls the genetic 
program involved in kidney develop-
ment. The identification of these new 
genes could be important in unraveling 
the complexity of molecular and cellular 
mechanisms of congenital renal diseases.
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